MX2019014940A - Moduladores de tetrahidropiridopirazinas del receptor 6 acoplado a la proteina g (gpr6). - Google Patents
Moduladores de tetrahidropiridopirazinas del receptor 6 acoplado a la proteina g (gpr6).Info
- Publication number
- MX2019014940A MX2019014940A MX2019014940A MX2019014940A MX2019014940A MX 2019014940 A MX2019014940 A MX 2019014940A MX 2019014940 A MX2019014940 A MX 2019014940A MX 2019014940 A MX2019014940 A MX 2019014940A MX 2019014940 A MX2019014940 A MX 2019014940A
- Authority
- MX
- Mexico
- Prior art keywords
- gpr6
- tetrahydropyridopyrazine
- modulators
- compound
- formula
- Prior art date
Links
- HOFCYSNYAFJTSI-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrido[2,3-b]pyrazine Chemical compound C1=CC=C2NCCNC2=N1 HOFCYSNYAFJTSI-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102100033861 G-protein coupled receptor 6 Human genes 0.000 abstract 1
- 101001069613 Homo sapiens G-protein coupled receptor 6 Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describe un compuesto de Fórmula 1, tal como se define en la memoria descriptiva y una sal farmacéuticamente aceptable de este. La presente descripción también se refiere a materiales y métodos para preparar el compuesto de Fórmula 1, a composiciones farmacéuticas que los contienen y a su uso para tratar enfermedades, trastornos y afecciones asociadas con GPR6.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762520430P | 2017-06-15 | 2017-06-15 | |
| US201762591247P | 2017-11-28 | 2017-11-28 | |
| US201862649856P | 2018-03-29 | 2018-03-29 | |
| US201862672261P | 2018-05-16 | 2018-05-16 | |
| PCT/US2018/037687 WO2018232202A1 (en) | 2017-06-15 | 2018-06-15 | Tetrahydropyridopyrazine modulators of gpr6 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019014940A true MX2019014940A (es) | 2020-02-19 |
Family
ID=64656005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014940A MX2019014940A (es) | 2017-06-15 | 2018-06-15 | Moduladores de tetrahidropiridopirazinas del receptor 6 acoplado a la proteina g (gpr6). |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US10406157B2 (es) |
| EP (1) | EP3638673B9 (es) |
| JP (2) | JP7460369B2 (es) |
| KR (1) | KR102802861B1 (es) |
| CN (1) | CN110730781B (es) |
| AU (1) | AU2018285677B2 (es) |
| CA (1) | CA3067032A1 (es) |
| CO (1) | CO2019015086A2 (es) |
| DK (1) | DK3638673T3 (es) |
| ES (1) | ES2988680T3 (es) |
| FI (1) | FI3638673T3 (es) |
| HR (1) | HRP20241231T1 (es) |
| HU (1) | HUE068346T2 (es) |
| IL (1) | IL271332B2 (es) |
| JO (1) | JOP20180057A1 (es) |
| LT (1) | LT3638673T (es) |
| MX (1) | MX2019014940A (es) |
| PH (1) | PH12019502792A1 (es) |
| PL (1) | PL3638673T3 (es) |
| PT (1) | PT3638673T (es) |
| RS (1) | RS66018B1 (es) |
| SG (1) | SG11201912149WA (es) |
| SI (1) | SI3638673T1 (es) |
| TW (1) | TWI775874B (es) |
| WO (1) | WO2018232202A1 (es) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| US7229557B2 (en) | 2004-02-04 | 2007-06-12 | Konec, Inc. | Method to separate stereoisomers |
| EP2451281A4 (en) | 2009-07-09 | 2013-03-13 | Merck Sharp & Dohme | TETRAHYDRONAPHTHYDRIN-orexin receptor Antagonist |
| JO3466B1 (ar) * | 2013-12-20 | 2020-07-05 | Takeda Pharmaceuticals Co | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 |
| AU2015218402B2 (en) * | 2014-02-14 | 2019-07-11 | Takeda Pharmaceutical Company Limited | Pyrazines modulators of GPR6 |
| WO2015123505A1 (en) | 2014-02-14 | 2015-08-20 | Takeda Pharmaceutical Company Limited | Pyridopyrazines modulators of gpr6 |
-
2017
- 2017-06-15 JO JOP/2018/0057A patent/JOP20180057A1/ar unknown
-
2018
- 2018-06-15 WO PCT/US2018/037687 patent/WO2018232202A1/en not_active Ceased
- 2018-06-15 PT PT188188296T patent/PT3638673T/pt unknown
- 2018-06-15 ES ES18818829T patent/ES2988680T3/es active Active
- 2018-06-15 CA CA3067032A patent/CA3067032A1/en active Pending
- 2018-06-15 KR KR1020197037207A patent/KR102802861B1/ko active Active
- 2018-06-15 CN CN201880038831.4A patent/CN110730781B/zh active Active
- 2018-06-15 MX MX2019014940A patent/MX2019014940A/es unknown
- 2018-06-15 TW TW107120685A patent/TWI775874B/zh active
- 2018-06-15 RS RS20241067A patent/RS66018B1/sr unknown
- 2018-06-15 SI SI201831159T patent/SI3638673T1/sl unknown
- 2018-06-15 PL PL18818829.6T patent/PL3638673T3/pl unknown
- 2018-06-15 JP JP2019563277A patent/JP7460369B2/ja active Active
- 2018-06-15 SG SG11201912149WA patent/SG11201912149WA/en unknown
- 2018-06-15 FI FIEP18818829.6T patent/FI3638673T3/fi active
- 2018-06-15 US US16/009,308 patent/US10406157B2/en active Active
- 2018-06-15 DK DK18818829.6T patent/DK3638673T3/da active
- 2018-06-15 HU HUE18818829A patent/HUE068346T2/hu unknown
- 2018-06-15 LT LTEPPCT/US2018/037687T patent/LT3638673T/lt unknown
- 2018-06-15 AU AU2018285677A patent/AU2018285677B2/en active Active
- 2018-06-15 HR HRP20241231TT patent/HRP20241231T1/hr unknown
- 2018-06-15 EP EP18818829.6A patent/EP3638673B9/en active Active
-
2019
- 2019-12-10 PH PH12019502792A patent/PH12019502792A1/en unknown
- 2019-12-11 IL IL271332A patent/IL271332B2/en unknown
- 2019-12-30 CO CONC2019/0015086A patent/CO2019015086A2/es unknown
-
2022
- 2022-10-05 JP JP2022160819A patent/JP7497400B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023003989A (es) | Compuestos, composiciones y metodos. | |
| DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
| CL2017001017A1 (es) | Nuevos compuestos de metil-piperidina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| MX2019004685A (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3f] isoquinolina utiles en el tratamiento del cancer. | |
| CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
| MX381707B (es) | Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen. | |
| MX376028B (es) | Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| CR20150056A (es) | Derivados de azaindol | |
| MX395013B (es) | Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrogenos y usos de los mismos | |
| UY37098A (es) | Moduladores de ror-gamma | |
| UY35376A (es) | Derivados de triazolona de piridinilo y piridinilo fusionado | |
| AR094553A1 (es) | Formas de oxadiazolpirazina | |
| AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| MX393586B (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue | |
| DOP2017000034A (es) | Compuestos de imidazopiridazina | |
| NI201800071A (es) | Compuestos de isoindol | |
| MX384392B (es) | Moduladores heterocíclicos de la síntesis de lípidos para su uso contra el cáncer e infecciones virales. | |
| MX2019011286A (es) | Carboxamidas heteroaromaticas sustituidas de piperidinilo y piperazinilo como moduladores de gpr6. | |
| CL2017002498A1 (es) | Piridopirimidinonas y su uso como modulares del receptor nmda | |
| MX2020003732A (es) | Derivado de anillo fusionado como inhibidor del receptor a2a. | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| AR107937A1 (es) | Compuestos de cinolin-4-amina y su uso en el tratamiento del cáncer | |
| UY35945A (es) | Derivados de azaindol | |
| MX2019014940A (es) | Moduladores de tetrahidropiridopirazinas del receptor 6 acoplado a la proteina g (gpr6). | |
| ECSP17045054A (es) | Derivados de fumagilol |